Weight Loss Medications

It's important to note that access from 23rd June does not necessarily mean doctors and healthcare professionals will begin prescribing from that date. Weight management services are locally commissioned and funded at an Integrated Care Board (ICB) level. At Salisbury Medical Practice we are waiting for information from the ICB regarding the rollout of weight loss injections via GP practices. The criteria for this service will be very limited and we will be in contact with any eligible patients in due course, there is no need to contact the practice regarding this topic in the meantime.  

Tirzepatide, also known as Mounjaro®, is a GLP1/GIP agonist mimicking gut hormones released by the body after eating, telling the brain you are full and slowing down the time it takes the stomach to empty.

The qualifying clinical criteria has been set out by NHS England identifying those at greatest risk of ill health, or who are experiencing severe ill health due to living with obesity meaning Tirzepatide is not accessible to everyone who wishes to use it. 

Patients who qualify for Tirzepatide must have a BMI of more than 40 and be living with at least 4 of the 5 stated weight-related health conditions, such as:
•    type 2 diabetes
•    high blood pressure
•    heart disease
•    obstructive sleep apnoea
•    abnormal blood fats (dyslipidaemia)

People who meet the criteria will be able to explore with their healthcare professional whether this is the right treatment for them. Access to the drug must be accompanied by wraparound care which will include support for people to make dietary changes and to increase physical activity.

Tirzepatide will be phased in gradually through a special agreement between NICE and the NHS in England, to make sure primary care services aren’t overwhelmed and can manage the extra demand safely. ICBs will be responsible for commissioning appropriate services which won't necessarily be through a patient's GP; community-based programmes and other non-GP primary care providers will also provide access.

Tirzepatide might not be clinically considered suitable for everyone and not everyone who meets the eligibility criteria will want to use it to support their weight loss. Other options are available including weight loss programmes which use tried and tested methods such as lifestyle changes and nutrition and physical activity advice.

For further information on weight management services including access to the NHS BMI calculator please visit our Self Help Centre.

Published: Jul 16, 2025